{"url_path":"/sec/mdcx/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1997296/0001062993-26-003060-index.html","accession_number":"0001062993-26-003060","cik":"0001997296","ticker":"MDCX","issuer_name":"Medicus Pharma Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1997296/0001062993-26-003060-index.html","primary_entity_key":"0001997296","primary_entity_name":"Medicus Pharma Ltd."},"word_count":402,"has_tables":true,"body_markdown":"**Item 5.07. Submission of Matters to a Vote of Security Holders.**\n\n**(a) Annual and Special Meeting**. On June 3, 2026, Medicus Pharma Ltd. (the \"Company\") held its 2026 Annual General and Special Meeting of Shareholders (the \"Meeting\"). The matters voted upon at the Meeting and the final results of such voting are set forth below. A more complete description of each proposal is set forth in the Company's definitive proxy statement filed with the Securities and Exchange Commission on May 4, 2026.\n\n**(b) Matters Voted Upon; Voting Results**. The following matters were submitted for a vote of the Company's shareholders.\n\nProposal 1. Shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's 2026 fiscal year and the authorization of the Company's board of directors (the \"Board\") to fix the auditors' remuneration and terms of engagement:\n\n**For**\n\n** **\n\n**Withhold**\n\n** **\n\n**Abstain**\n\n** **\n\n**Broker Non-Votes**\n\n28,308,860\n\n \n\n756,378\n\n \n\nN/A\n\n \n\n0\n\nProposal 2. Shareholders elected all nine of the directors nominated by the Board to serve for one-year terms, until our 2027 annual meeting of shareholders or until their successors are duly elected or appointed, unless they resign, are removed, or become disqualified in accordance with the Articles of Incorporation of the Company (the \"Articles\") or the *Business Corporations Act* (Ontario):\n\n**Name**\n** **\n**For**\n** **\n**Withhold**\n** **\n**Abstain**\n** **\n**Broker Non-Votes**\n\nWilliam L. Ashton\n \n15,181,189\n \n354,284\n \nN/A\n \n13,529,765\n\nDr. Raza Bokhari\n \n15,068,465\n \n467,008\n \nN/A\n \n13,529,765\n\nRobert J. Ciaruffoli\n \n15,186,431\n \n349,042\n \nN/A\n \n13,529,765\n\nBarry Fishman\n \n15,189,646\n \n345,827\n \nN/A\n \n13,529,765\n\nDr. Larry Kaiser\n \n15,198,014\n \n337,459\n \nN/A\n \n13,529,765\n\nPatrick Mahaffy\n \n15,193,804\n \n341,669\n \nN/A\n \n13,529,765\n\nDr. Sara R. May\n \n15,192,642\n \n342,831\n \nN/A\n \n13,529,765\n\nHon. Cathy McMorris Rodgers\n \n15,178,833\n \n356,640\n \nN/A\n \n13,529,765\n\nAjay Raju\n \n15,190,298\n \n345,175\n \nN/A\n \n13,529,765\n\nProposal 3. Shareholders approved the special resolution authorizing the Board, in its discretion, to effect a consolidation of the Company's common shares, no par value (the \"Common Shares\") on the basis of a consolidation ratio to be determined by the Board, up to a maximum ratio of 50 pre-consolidation Common Shares for every one post-consolidation Common Share, if the Board determines such a consolidation is necessary or desirable, including, without limitation, for the purpose of meeting any applicable stock exchange or regulatory requirements. Shareholder approval of this Proposal 3 required the affirmative vote of at least two-thirds of the votes cast by the shareholders present at the Meeting in person or by proxy:\n\n**For**\n \n**Against**\n** **\n**Abstain**\n** **\n**Broker Non-Votes**\n\n26,729,776\n \n2,335,461\n \nN/A\n \n1"}